3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
127
Colonic Neoplasms
54
Rectal Neoplasms
49
Carcinoma, Hepatocellular
29
Stomach Neoplasms
22
Neoplasm Metastasis
22
Neoplasms
11
Pancreatic Neoplasms
9
Cholangiocarcinoma
8
Adenocarcinoma Of Esophagus
8
Esophageal Neoplasms
7
Liver Neoplasms
6
Biliary Tract Neoplasms
5
Recurrence
4
Ovarian Neoplasms
4
Gastrointestinal Neoplasms
4
Esophageal Squamous Cell Carcinoma
3
Digestive System Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Adenocarcinoma
3
Unresectable Metastatic Colorectal Cancer
2
Peritoneal Neoplasms
2
Neoplastic Cells, Circulating
2
Intestinal Neoplasms
2
Gastrointestinal Diseases
2
Gallbladder Neoplasms
2
Colorectal Cancer Metastatic
2
Cirrhosis, Familial, with Pulmonary Hypertension
2
Squamous Cell Carcinoma of Head and Neck
1
Interventions
Gemcitabine
40
Cisplatin
24
Capecitabine
21
Fluorouracil
19
Oxaliplatin
17
Leucovorin
14
pembrolizumab
9
Irinotecan
8
Radiotherapy
7
Erlotinib Hydrochloride
7
durvalumab
6
Sorafenib
4
Magnetic Resonance Spectroscopy
4
Carboplatin
4
trametinib
3
Trastuzumab
3
Photochemotherapy
3
Long-Term Synaptic Depression
3
Interleukin-12 Subunit p35
3
Filgrastim
3
Dihematoporphyrin Ether
3
Dexamethasone
3
Chemotherapy, Adjuvant
3
trifluridine tipiracil drug combination
2
tivozanib
2
tislelizumab
2
spartalizumab
2
regorafenib
2
olaparib
2
dehydroftorafur
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Bile Duct Neoplasms
×
Folfox protocol
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts